Hydroflumethiazide
FDA-approved product (tablet, oral), marketed as Diucardin, Hydroflumethiazide, Saluron.
- Registered studies
- 1
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Thiazides, plain; Thiazides, combinations with psycholeptics and/or analgesics
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae18.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis67.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Hydroflumethiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Quinapril HydrochlorideExisting use: Cardiovascular disease, Diabetes mellitus, Heart failure and 3 more62.3% AI-predicted activityagainst M. tuberculosis33 registered studies
- BelzutifanExisting use: Clear cell renal carcinoma, Hemangioblastoma, Neoplasm and 4 more62.2% AI-predicted activityagainst M. tuberculosis45 registered studies
- ChlorprothixeneExisting use: Psychosis62.2% AI-predicted activityagainst M. tuberculosis4 registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma62.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Pacritinib CitrateExisting use: Neoplasm, Polycythemia vera, Primary myelofibrosis62.2% AI-predicted activityagainst M. tuberculosis2 registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more62.1% AI-predicted activityagainst M. tuberculosis44 registered studies
- Methdilazine HydrochlorideExisting use: Allergic disease62.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more62.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AdagrasibExisting use: Neoplasm, Non-small cell lung carcinoma61.9% AI-predicted activityagainst M. tuberculosis40 registered studies
- TrandolaprilExisting use: Cardiovascular disease, Heart failure, Hypertension and 2 more61.9% AI-predicted activityagainst M. tuberculosis29 registered studies
- Almotriptan MalateExisting use: Migraine disorder61.8% AI-predicted activityagainst M. tuberculosis16 registered studies
- AsenapineExisting use: Bipolar disorder, Bipolar I disorder, Psychosis and 1 more61.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension
NCT01260857 · start 2013-03
Registered record
- Registry ID
- NCT01260857
- Conditions
- Hypertension
- Interventions
- Aldazide
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Withdrawn
- Start
- 2013-03
- Completion
- 2015-02
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionAldazidePhaseNot recordedRegistry statusWithdrawn